Clinical Trial Update: Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating flavored oral irinotecan VAL-413 (Orotecan) with temozolomide for recurrent pediatric solid tumors is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma
• Hepatoblastoma
• Medulloblastoma
• Neuroblastoma
• Rhabdomyosarcoma
• Solid Tumors

Drugs mentioned

• Orotecan (VAL-413) (irinotecan)
• Temozolomide (Temozolomide)

Snippet

Sponsor: Valent Technologies, LLC | Conditions: Solid Tumors, Neuroblastoma | Phase 1 | Status: RECRUITING